Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Solvonis Therapeutics PLC

SVNS.L ✓ COMPLIANTFree checks used up today ☆ Track — members

LSE · Healthcare · Biotechnology & Medical Research ·

UK Micro Cap Analyst: BUY

Last Close

$0.00

▲ +0.00%

Market Cap $12.17M · Vol 13.86M

Price charts are for members

Interactive price history from intraday to 5 years, on every stock and ETF.

See plans

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$12.17M

Micro Cap

Div Yield

N/A

EPS Growth

+31.33%

YoY

RSI (14)

38.46

Momentum

Beta

1.27

vs Market

52W High

$0.01

71.31% below

52W Low

$0.00

13.96% above

Volume

13.86M

Avg 20.03M

P/B

3.41

Price-to-book

ROE

N/A

Return on equity

Free Float

67.69%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Solvonis Therapeutics PLC (SVNS.L) stock is Shariah compliant

You’ve used your 10 free compliance checks today

Choose a plan

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share.Members see the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does SVNS.L pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+0.00%

-23.33%

-39.15%

-51.06%

YTD

-62.90%

-65.15%

-94.68%

N/A

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-7,733,452.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	N/A
ROA · ROIC	-106.41% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	3.41
P/FCF	N/A
EPS Growth	+31.33%
Outstanding Shares	7.90B

Technical Indicators

50-Day SMA	$0.00
200-Day SMA	$0.00
RSI (14)	38.46
Beta	1.27
52-Week High	$0.01
52-Week Low	$0.00

Volume Today	13.86M
Avg Daily Volume (30D)	20.03M
Relative Volume	0.69x
Volatility (10D)	44.45
Volatility (30D)	58.66
Free Float	67.69%

Analyst Consensus

BUY

Current Price $0.00

Mean Target $0.02

52W Low$0.00 52W High$0.01

Current

Target

$0.00 $0.01

Current Analyst target

+1,397.71% upside potential · 2 analysts

Identifiers

ExchangeLSE

FIGIBBG0147DYM99

ISINGB00BMD1Z199

CountryUK

Sub-IndustryBiotechnology & Medical Research (NEC)

Earnings DateN/A

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LONN.S Lonza Group AG +0.59% ONC BeOne Medicines AG +4.23% 068270.KS Celltrion, Inc. +1.11% MEDP Medpace Holdings, Inc. +1.94% ABVX Abivax SA -1.51%

Company Profile

Solvonis Therapeutics PLC is a clinical-stage biotechnology company developing treatments for addiction and mental health disorders. The Company is advancing a differentiated pipeline of repurposed and novel compounds targeting high-burden neuropsychiatric conditions with significant unmet need. It is focused on Alcohol Use Disorder (AUD), which affects over 40 million people across the United States, United Kingdom, and EU4 markets, and Post-Traumatic Stress Disorder (PTSD), impacting more than 13 million adults in the United States and approximately 20 million across those same regions. AUD is characterized by compulsive, harmful drinking, and is associated with significant health risks, including chronic diseases, mental health conditions and accidents, injuries and violence. PTSD is a complex and debilitating mental health condition that develops in some people who have experienced traumatic events, for example violence, an accident, war or a natural disaster.